Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

[1] Jemal A(2011)Global cancer statistics CA Cancer J Clin 61 69-90

[2] Bray F(2012)Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy Adv Urol 2012 921674-628

[3] Center MM(2005)Fluorocholine PET/CT in patients with prostate cancer: initial experience Radiology 235 623-983

[4] Ferlay J(2008)The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer Eur J Nucl Med Mol Imaging 35 976-1569

[5] Ward E(2008)Prostate biopsy guided by 18F-fluorocholine PET in men with persistently elevated PSA levels Eur J Nucl Med Mol Imaging 35 1567-2018

[6] Forman D(2006)Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of 18F-fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection J Urol 176 2014-263

[7] Kosuri S(2008)Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 253-1398

[8] Akhtar NH(2006)18F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 1387-904

[9] Smith M(2008)Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer Radiol Med 113 895-332

[10] Osborne JR(2010)Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer J Med Imaging Radiat Oncol 54 325-48

[1] Jemal A(2011)Global cancer statistics CA Cancer J Clin 61 69-90

[2] Bray F(2012)Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy Adv Urol 2012 921674-628

[3] Center MM(2005)Fluorocholine PET/CT in patients with prostate cancer: initial experience Radiology 235 623-983

[4] Ferlay J(2008)The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer Eur J Nucl Med Mol Imaging 35 976-1569

[5] Ward E(2008)Prostate biopsy guided by 18F-fluorocholine PET in men with persistently elevated PSA levels Eur J Nucl Med Mol Imaging 35 1567-2018

[6] Forman D(2006)Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of 18F-fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection J Urol 176 2014-263

[7] Kosuri S(2008)Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 253-1398

[8] Akhtar NH(2006)18F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 1387-904

[9] Smith M(2008)Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer Radiol Med 113 895-332

[10] Osborne JR(2010)Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer J Med Imaging Radiat Oncol 54 325-48